Update on Hepatitis C 2017
DOI: 10.5772/intechopen.70794
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacogenomic Testing in the Era of Patient-Tailored HCV Treatment

Abstract: Hepatitis C affects approximately 180 million people worldwide, with 3-4 million newly infected each year. Hepatitis C virus (HCV) has been classified into seven different genotype categories, wherein HCV genotype 1 (HCV-1) is the most prevalent. To date, there is still no vaccine available against HCV infection. Until recently, combination therapy of pegylated interferon-a (PegIFN) and ribavirin (RBV) has been the standard of care. Nevertheless, for many patients, particularly those infected with HCV genotype… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 82 publications
(115 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?